PerkinElmer

Noninvasive Prenatal Testing

Noninvasive prenatal testing (NIPT) consists of analyzing cell-free DNA (cfDNA) circulating in the maternal blood in order to detect Down's syndrome and other fetal chromosomal abnormalities. From a simple blood test, NIPT has demonstrated its superior efficacy to detect trisomies thereby reducing the number of further invasive testing procedures.

By enabling early access to reliable results, NIPT has quickly been integrated in various screening programs across the world. However, cell-free DNA testing for aneuploidy screening has been so far limited by the complexity, cost and capacity of existing NIPT technologies.

Vanadis® NIPT system is built for all

Vanadis NIPT system is an automated solution designed to solve these challenges and allow laboratories to screen more women with NIPT. Indeed, it is the only NIPT screening platform to enable targeted cfDNA analysis without PCR amplification and sequencing, instead capturing target fragments of chromosomes 21, 18 and 13 and labeling them for counting.




Products may not be licensed in accordance with the laws in all countries, such as the United States and Canada. Please check with your local representative for availability.

Featured Content

Vanadis NIPT System Brochure

With our high-throughput Vanadis NIPT solution, we’re taking much of the complexity out of cell-free DNA (cfDNA) testing, making it accessible to more women – a ...

Learn More

Vanadis NIPT: An Automated System for High-Precision Prenatal Screening

This whitepaper describes the importance of assay precision in achieving high detection rate of fetal aneuploidies. Furthermore, the paper shows how the Vanadis ...

Learn More

SCIENTIFIC REPORTS: Imaging single DNA molecules for high precision NIPT

This publication From Nature Scientific Reports presents an assessment of the Vanadis NIPT assay in terms of analytical precision and clinical feasibility, and ...

Learn More

Contact us to speak with a specialist